Market Overview

H.C. Wainwright: Acadia Is More Than A One-Trick Pony

Share:
H.C. Wainwright: Acadia Is More Than A One-Trick Pony

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on Tuesday reported second-quarter earnings, which consisted of a better than expected loss per share (53 cents versus expectations for 62 cents)and a revenue beat ($35.6 million versus expectations for $32.03 million).

Sales of the company's only therapy, Nuplazid, saw a notable uptake from $5.27 million in the same quarter a year ago.

The Analyst

H.C. Wainwright & Co's Andrew Fein.

The Rating

Fein maintains a Buy rating on Acadia's stock with an unchanged $60 price target.

The Thesis

Acadia's third-quarter earnings, highlighted by strong sales of Nuplazid and a more encouraging full-year revenue guidance shows the "solid underlying market dynamics and validation" of Nuplazid's value, Fein said in his report.

Nuplazid's momentum seen in the quarter could be sustained over time due to various factors, including specialty LTC, awareness campaigns, patient and physician satisfaction, and psychiatrists/neurologists engagement.

The company could see success in its pimavanserin therapy which has "multiple shots on goal to expand the label into other patient populations, and it may be positioned as a general antipsychotic drug."

Related Links:

Selling The News In Acadia Pharmaceuticals

Pros And Cons Of All The News Out Of Acadia Pharma This Week

Latest Ratings for ACAD

DateFirmActionFromTo
Mar 2020Goldman SachsUpgradesNeutralBuy
Mar 2020CitigroupInitiates Coverage OnBuy
Mar 2020JP MorganMaintainsNeutral

View More Analyst Ratings for ACAD
View the Latest Analyst Ratings

 

Related Articles (ACAD)

View Comments and Join the Discussion!

Posted-In: Andrew Fein HC Wainwright NUPLAZID PharmaceuticalAnalyst Color Earnings News Analyst Ratings Best of Benzinga

Latest Ratings

StockFirmActionPT
BBCanaccord GenuityMaintains6.0
ATROCanaccord GenuityMaintains14.0
GMCFRAMaintains20.0
ZGCitigroupMaintains44.0
XYLCitigroupMaintains68.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com